Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.
Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease.
IgGs containing λ- and κ-type light chains and of all subclasses (IgG1-IgG4) from the sera of patients with autoimmune diseases and viral and bacterial infections hydrolyze DNA.
Principles of DNA-Based Gut Microbiota Assessment and Therapeutic Efficacy of Fecal Microbiota Transplantation in Gastrointestinal Diseases.
The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings.
The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway - Commentary.
Inflammation Markers in Multiple Sclerosis: CXCL16 Reflects and May Also Predict Disease Activity.
Glia Maturation Factor Induces Interleukin-33 Release from Astrocytes: Implications for Neurodegenerative Diseases.
ALCAM - Novel multiple sclerosis locus interfering with HLA-DRB1*1501.
Tried-and-True Antibiotic May Block Conversion to MS
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes.
Exploring the role of interleukin-22 in neurological and autoimmune disorders.
Inducible Expression of a Truncated Form of Tau in Oligodendrocytes Elicits Gait Abnormalities and a Decrease in Myelin: Implications for Selective CNS Degenerative Diseases.
Atypical Optic Neuritis.
A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis.
Role of vitamin D in acquired immune and autoimmune diseases.
Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study.
Fingolimod Reduces Direct Medical Costs Compared to Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis in the Netherlands.
Case of Type 1 Diabetes Mellitus Following Interferon β-1a Treatment for Multiple Sclerosis.
EDSS variability before randomization may limit treatment discovery in primary progressive MS.
Concomitant analysis of arterial, venous, and CSF flows using phase-contrast MRI: a quantitative comparison between MS patients and healthy controls.
Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells.
Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis.
Life on hold: the experience of living with neuromyelitis optica.

Pages